Lucid-21-302 (Lucid-MS) for Protecting Myelin and Neurons and Preventing Disease Progression in Multiple Sclerosis: First-In-Human Phase-1 Dose Escalation Study in Healthy Volunteers

Authors
Category Primary study
ConferenceACTRIMS Forum 2024
Year 2024
This article has no abstract
Epistemonikos ID: 5106fbd938ad3eefd384d9c99dda3c1dcb1970e3
First added on: Dec 05, 2025